Biocon Biologics gets Japenese nod for Psoriasis Vulgaris injection Ustekinumab BS Ruchika Sharma7 Jan 2025 1:15 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the...
Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis Ruchika Sharma2 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the U.S. Food ...
Winter has no significant impact on symptoms including fatigue and pain in psoriatic arthritis patients: Study Jacinthlyn Sylvia22 Oct 2024 8:15 PM ISTA new study published in The Journal of Rheumatology found that the individuals with psoriatic arthritis (PsA) did not report a substantial change in...
Psoriasis and Psoriatic Arthritis Linked to Higher Risk of Polyneuropathy Due to Contributing Factors: Study Medha Baranwal6 Sept 2024 5:15 AM ISTItaly: Psoriasis and psoriatic arthritis are associated with a higher risk of polyneuropathy, which appears to stem from a greater prevalence of...
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, Japan Ruchika Sharma29 Aug 2024 12:30 PM ISTBangalore: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced today that the...
Sandoz unveils biosimilar Pyzchiva across Europe to treat chronic inflammatory diseases Ruchika Sharma28 July 2024 10:30 AM ISTBasel: Sandoz has announced the launch of Pyzchiva (ustekinumab) across Europe. Pyzchiva, developed and registered by Samsung Bioepis, a ustekinumab...
CDSCO Panel approves Novartis Healthcare for selective use of Secukinumab dose up to 300 mg Dr. Divya Colin14 July 2024 6:00 PM ISTNew Delhi: Reviewing the justification presented by the drug major Novartis Healthcare for the monoclonal antibody Secukinumab, the Subject Expert...
New study reveals link between psoriatic arthritis and elevated aortic stiffness Medha Baranwal14 Jun 2024 8:00 AM ISTGermany: In a groundbreaking discovery, researchers have uncovered a significant association between psoriatic arthritis (PsA) and an elevated risk of...
Higher number of biologics required for control of coexisting PsA and atopic dermatitis: Study Jacinthlyn Sylvia13 May 2024 6:45 AM ISTA recent study published in the Journal of Personalized Medicine observed new insights regarding the treatment of psoriatic arthritis (PsA) and its...
Lupin unveils Rymti biosimilar Etanercept in Canada Ruchika Sharma5 May 2024 10:00 AM ISTMumbai: Global pharma major Lupin Limited has announced the launch of Rymti, Lupin's first biosimilar in Canada, through its partner Sandoz...
Secukinumab may significantly alleviate symptoms of psoriatic arthritis, finds research Dr Riya Dave24 April 2024 7:45 PM ISTResearchers have found that a dose of 300 mg of secukinumab can significantly alleviate symptoms of psoriatic arthritis (PsA) compared to placebo,...
